

Liver Failure

## Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

**Trial Status**  
Completed

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT02621047 2015-002976-25  
NP29783

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a multicenter, non-randomized, single-dose, open-label study conducted in male and surgically sterile or post-menopausal female participants with stable chronic hepatic impairment and in healthy participants matched by age, gender, and body weight to assess the effect of hepatic impairment on the pharmacokinetics of alectinib.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT02621047 2015-002976-25 NP29783**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>= 18 Years & <= 70 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---